03/17/2017

NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Non-Small Cell Lung Cancer.

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Non-Small Cell Lung Cancer. These NCCN Guidelines^® are currently available as Version 5.2017. 

• Metastatic Disease – ALK Rearrangement Positive
  • First-line Therapy (NSCL-20)
    • ALK rearrangement discovered prior to first-line chemotherapy: Ceritinib added as a category 1 treatment option.
    • ALK rearrangement discovered during first-line chemotherapy: Complete planned chemotherapy, including maintenance therapy, or interrupt, followed by crizotinib or ceritinib.
  • Subsequent Therapy (NSCL-21)
    • Asymptomatic, Brain and Systemic isolated lesions: "continue ceritinib" added as a treatment option.
    • Footnote "ss" added: If not previously given.
• The Discussion section has been updated to reflect the changes in the algorithm. 

*For your reference, the previous update (Version 4.2017) to the NCCN Guidelines for Non-Small Cell Lung Cancer, published on January 18, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium, the NCCN Biomarkers Compendium^®, the NCCN Templates^®, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.